We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | 장 마감 후 (AMC) | $1.75 | — | — | $623.99M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $2.29 | — | — | $585.4M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-39.89 | — | — | $1.9B |
Consensus PT $297 · 5 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 01. | Wells Fargo | — | 의견 유지 | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 04. 07. | Citigroup | — | 투자의견 하향 | Buy → Neutral | — | Citigroup: Buy → Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-62.61 | — | — | $1.25B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Stored first · Google News · Yahoo Finance (English)
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V - GuruFocus
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V GuruFocus
[144] BIO-RAD LABORATORIES, INC. SEC Filing - Stock Titan
[144] BIO-RAD LABORATORIES, INC. SEC Filing Stock Titan
How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake - simplywall.st
How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake simplywall.st